FI20031793A0 - Uusi anti-proliferatiivinen farmaseuttinen koostumus - Google Patents

Uusi anti-proliferatiivinen farmaseuttinen koostumus

Info

Publication number
FI20031793A0
FI20031793A0 FI20031793A FI20031793A FI20031793A0 FI 20031793 A0 FI20031793 A0 FI 20031793A0 FI 20031793 A FI20031793 A FI 20031793A FI 20031793 A FI20031793 A FI 20031793A FI 20031793 A0 FI20031793 A0 FI 20031793A0
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
agent
new anti
animal
person
Prior art date
Application number
FI20031793A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Lasse Leino
Jarmo Laihia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20031793(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lasse Leino, Jarmo Laihia filed Critical Lasse Leino
Priority to FI20031793A priority Critical patent/FI20031793A0/fi
Publication of FI20031793A0 publication Critical patent/FI20031793A0/fi
Priority to DE602004014187T priority patent/DE602004014187D1/de
Priority to SI200430757T priority patent/SI1691805T1/sl
Priority to AT04798326T priority patent/ATE396723T1/de
Priority to PCT/FI2004/000717 priority patent/WO2005056007A1/en
Priority to US10/565,202 priority patent/US20060189691A1/en
Priority to JP2006543562A priority patent/JP4825680B2/ja
Priority to ZA200602940A priority patent/ZA200602940B/en
Priority to CN2004800362562A priority patent/CN1889950B/zh
Priority to EP04798326A priority patent/EP1691805B1/en
Priority to ES04798326T priority patent/ES2303113T3/es
Priority to DK04798326T priority patent/DK1691805T3/da
Priority to PL04798326T priority patent/PL1691805T3/pl
Priority to CA2544720A priority patent/CA2544720C/en
Priority to AU2004296570A priority patent/AU2004296570B2/en
Priority to PT04798326T priority patent/PT1691805E/pt
Priority to US11/408,056 priority patent/US8338475B2/en
Priority to CY20081100681T priority patent/CY1108163T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FI20031793A 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus FI20031793A0 (fi)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus
AU2004296570A AU2004296570B2 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
PT04798326T PT1691805E (pt) 2003-12-09 2004-11-26 Utilização de ácido urocânico capaz de acidificar o citoplasma celular e para prevenir ou interromper a proliferação celular numa pessoa
ZA200602940A ZA200602940B (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
ES04798326T ES2303113T3 (es) 2003-12-09 2004-11-26 El uso de acido urocanico para acidificar el citoplasma de la celula y para prevenir o parar la proliferacion celular en una persona.
AT04798326T ATE396723T1 (de) 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person
PCT/FI2004/000717 WO2005056007A1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
US10/565,202 US20060189691A1 (en) 2003-12-09 2004-11-26 Use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
JP2006543562A JP4825680B2 (ja) 2003-12-09 2004-11-26 ヒトにおいて細胞増殖を抑制または停止するための細胞の細胞質を酸性化することができるウロカニン酸の使用
DE602004014187T DE602004014187D1 (de) 2003-12-09 2004-11-26 Verwendung von urocansäure zur ansäuerung des zellzytoplasmas und zur prävention oder zum aufhalten der zellproliferation in einer person
CN2004800362562A CN1889950B (zh) 2003-12-09 2004-11-26 尿刊酸用于制备酸化细胞质和预防或停止人体内细胞增殖的药物的用途
EP04798326A EP1691805B1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
SI200430757T SI1691805T1 (sl) 2003-12-09 2004-11-26 Uporaba urokanske kisline za nakisanje celične citoplazme in za preprečevanje ali zaustavitev celične proliferacije pri osebi
DK04798326T DK1691805T3 (da) 2003-12-09 2004-11-26 Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre
PL04798326T PL1691805T3 (pl) 2003-12-09 2004-11-26 Zastosowanie kwasu urokanowego zdolnego do zakwaszania cytoplazmy komórkowej i do zapobiegania lub zatrzymywania proliferacji komórkowej
CA2544720A CA2544720C (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person
US11/408,056 US8338475B2 (en) 2003-12-09 2006-04-21 Anti-proliferative pharmaceutical composition
CY20081100681T CY1108163T1 (el) 2003-12-09 2008-06-30 Η χρηση ουροκανικου οξεος ως παραγοντας οξινισης του κυτοπλασματος κυτταρου και για την αποτροπη ή συγκρατηση του κυτταρικου πολλαπλασιασμου σε ανθρωπο

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
FI20031793A0 true FI20031793A0 (fi) 2003-12-09

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus

Country Status (17)

Country Link
US (2) US20060189691A1 (zh)
EP (1) EP1691805B1 (zh)
JP (1) JP4825680B2 (zh)
CN (1) CN1889950B (zh)
AT (1) ATE396723T1 (zh)
AU (1) AU2004296570B2 (zh)
CA (1) CA2544720C (zh)
CY (1) CY1108163T1 (zh)
DE (1) DE602004014187D1 (zh)
DK (1) DK1691805T3 (zh)
ES (1) ES2303113T3 (zh)
FI (1) FI20031793A0 (zh)
PL (1) PL1691805T3 (zh)
PT (1) PT1691805E (zh)
SI (1) SI1691805T1 (zh)
WO (1) WO2005056007A1 (zh)
ZA (1) ZA200602940B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126058T1 (de) * 1990-06-29 1995-08-15 Bode Chemie Gmbh & Co Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsäure.
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
WO1997047355A1 (en) * 1996-06-12 1997-12-18 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
JP2003530850A (ja) * 2000-04-14 2003-10-21 ユニバーシティー オブ サウス カロライナ リサーチ ファウンデーション 生物活性ヒスチジンアンモニアリアーゼのクローニング、過剰発現および治療用途
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
CA2544720A1 (en) 2005-06-23
US20060189692A1 (en) 2006-08-24
CN1889950A (zh) 2007-01-03
EP1691805A1 (en) 2006-08-23
CN1889950B (zh) 2011-02-09
AU2004296570A1 (en) 2005-06-23
CA2544720C (en) 2012-01-03
US20060189691A1 (en) 2006-08-24
ZA200602940B (en) 2007-07-25
ATE396723T1 (de) 2008-06-15
CY1108163T1 (el) 2014-02-12
JP4825680B2 (ja) 2011-11-30
PL1691805T3 (pl) 2008-11-28
DE602004014187D1 (de) 2008-07-10
AU2004296570B2 (en) 2011-01-06
WO2005056007A1 (en) 2005-06-23
PT1691805E (pt) 2008-06-12
EP1691805B1 (en) 2008-05-28
ES2303113T3 (es) 2008-08-01
DK1691805T3 (da) 2008-10-06
JP2007513927A (ja) 2007-05-31
SI1691805T1 (sl) 2008-08-31
US8338475B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
SE9900961D0 (sv) Novel compounds
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
TW200606164A (en) New compounds
SE0100569D0 (sv) New compounds
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
SE9802208D0 (sv) Novel compounds
SE9802209D0 (sv) Novel compounds
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
FI20031793A0 (fi) Uusi anti-proliferatiivinen farmaseuttinen koostumus
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
SE0000303D0 (sv) Novel compounds
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
SE0401343D0 (sv) Therapeutic compounds: Pyridine N oxide as scaffold
DE60312215D1 (de) Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer
SE9802207D0 (sv) Novel compounds
SE0401716D0 (sv) New compounds

Legal Events

Date Code Title Description
FD Application lapsed